Get the Stockscreener App
15.42
2.46%
0.37
After Hours:
15.45
0.03
+0.19%
Cvrx Inc stock is traded at $15.42, with a volume of 445.77K.
It is up +2.46% in the last 24 hours and up +75.63% over the past month.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
See More
Previous Close:
$15.05
Open:
$15.03
24h Volume:
445.77K
Relative Volume:
1.37
Market Cap:
$373.22M
Revenue:
$39.30M
Net Income/Loss:
$-41.20M
P/E Ratio:
-7.3429
EPS:
-2.1
Net Cash Flow:
$-39.61M
1W Performance:
+43.58%
1M Performance:
+75.63%
6M Performance:
+67.25%
1Y Performance:
-12.44%
1-Day Range:
$14.82
$15.49
1-Week Range:
$10.47
$15.77
52-Week Range:
$6.40
$33.13
Cvrx Inc Stock (CVRX) Company Profile
Name
Cvrx Inc
Sector
Industry
Phone
(763) 416-2850
Address
9201 WEST BROADWAY AVENUE, MINNEAPOLIS
Cvrx Inc Stock (CVRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-10-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-11-24 | Reiterated | Lake Street | Buy |
| May-01-24 | Resumed | Craig Hallum | Buy |
| May-01-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-01-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-31-23 | Initiated | Lake Street | Buy |
| Jul-18-22 | Initiated | Craig Hallum | Buy |
| Jul-26-21 | Initiated | Canaccord Genuity | Buy |
| Jul-26-21 | Initiated | Piper Sandler | Overweight |
| Jul-26-21 | Initiated | William Blair | Outperform |
View All
Cvrx Inc Stock (CVRX) Latest News
Craig Hallum Issues Positive Forecast for CVRx (NASDAQ:CVRX) Stock Price - MarketBeat
CVRx earns Medicare win for Barostim procedure - Mass Device
CVRx gains CMS payment classification for Barostim - Investing.com
CVRx Announces Positive Outpatient Payment for Barostim Procedure in 2025 - GlobeNewswire
Emerald Mutual Fund Advisers Trust Has $2.54 Million Stock Holdings in CVRx, Inc. (NASDAQ:CVRX) - MarketBeat
CVRx, Inc. (NASDAQ:CVRX) Q3 2024 Earnings Call Transcript - MSN
FY2024 EPS Estimates for CVRx Lowered by Cantor Fitzgerald - MarketBeat
Analyst Estimates: Here's What Brokers Think Of CVRx, Inc. (NASDAQ:CVRX) After Its Third-Quarter Report - Simply Wall St
CVRx, Inc. (NASDAQ:CVRX) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year - Yahoo Finance
CVRx (CVRX) Reports Q3 Loss, Tops Revenue Estimates - MSN
How the (CVRX) price action is used to our Advantage - Stock Traders Daily
Canaccord lifts CVRx stock target, keeps buy rating on strong Q3 results By Investing.com - Investing.com South Africa
Canaccord lifts CVRx stock target, keeps buy rating on strong Q3 results - Investing.com
Earnings call: CVRx reports robust Q3 growth, eyes future reimbursement wins - Investing.com India
Canaccord Genuity Group Increases CVRx (NASDAQ:CVRX) Price Target to $17.00 - MarketBeat
CVRx (NASDAQ:CVRX) Given "Overweight" Rating at Piper Sandler - MarketBeat
CVRx Reports Strong Revenue Growth in Q3 2024 - TipRanks
CVRx earnings missed by $0.10, revenue topped estimates - Investing.com Canada
CVRx: Q3 Earnings Snapshot - The Advocate
CVRx Reports Third Quarter 2024 Financial and Operating Results - GlobeNewswire
CVRx Inc Q3 2024 Earnings: Revenue Hits $13.4M, EPS at -$0.57, S - GuruFocus.com
CVRx, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
CVRx (CVRX) Price Target Increased by 10.54% to 33.15 - MSN
CVRx's SWOT analysis: barostim maker's stock faces reimbursement hurdles By Investing.com - Investing.com South Africa
CVRx's SWOT analysis: barostim maker's stock faces reimbursement hurdles - Investing.com India
CVRx (NASDAQ:CVRX) Receives Overweight Rating from Cantor Fitzgerald - MarketBeat
CVRx, Inc. (NASDAQ:CVRX) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Cantor Fitzgerald stays positive on CVRx, reaffirms $14 stock PT after survey - Investing.com
CVRx, Inc. (NASDAQ:CVRX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
CVRx (CVRX) Set to Announce Earnings on Tuesday - MarketBeat
CVRx, Inc. Shares Surge Following Key Heart Failure Treatment Approval - Stocks Telegraph
CVRx (CVRX) Soars 17.2%: Is Further Upside Left in the Stock? - Yahoo Finance
Canaccord maintains Buy rating on CVRx stock - Investing.com
Canaccord maintains Buy rating on CVRx stock By Investing.com - Investing.com UK
CVRx announces new CPT Category I codes for Barostim heart failure therapy - Yahoo Finance
AMA approves new codes for heart failure therapy By Investing.com - Investing.com Australia
CVRx announces new CPT Category I codes for Barostim - Yahoo Finance
AMA approves new codes for heart failure therapy - Investing.com
CVRx announces new CPT® Category I codes for Barostim - The Manila Times
CVRx to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call on October 29, 2024 - The Manila Times
Investors Still Waiting For A Pull Back In CVRx, Inc. (NASDAQ:CVRX) - Simply Wall St
(CVRX) Technical Data - Stock Traders Daily
CVRx secures additional $20 million loan tranche By Investing.com - Investing.com Australia
CVRx secures additional $20 million loan tranche - Investing.com India
Cvrx Inc Stock (CVRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cvrx Inc Stock (CVRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SLATTERY JOSEPH P | Director |
Aug 08 '24 |
Buy |
8.24 |
3,000 |
24,716 |
27,645 |
| SLATTERY JOSEPH P | Director |
Aug 06 '24 |
Buy |
9.09 |
2,500 |
22,725 |
24,645 |
| Hykes Kevin | PRES & CEO |
Aug 05 '24 |
Buy |
8.36 |
30,000 |
250,767 |
30,000 |
0.47%
1.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):